MODAG, a German biotechnology company, announced that it would begin an in-patient clinical trial of anle138b, a disease-modifying treatment for synucleinopathies such as multiple system atrophy (MSA) and Parkinson’s disease (PD).
The company completed a clinical trial of anle138b in healthy volunteers in August 2020, in which it demonstrated excellent safety and tolerability. The newly initiated in-patient trial, supported by a grant from The Michael J. Fox Foundation for Parkinson’s Research, will study the safety, tolerability, and pharmacokinetics of anle138b in patients with PD, and will allow researchers to establish an optimal dosing schedule for use in future studies.
Anle138b is a small molecule that binds to and prevents the accumulation of alpha-synuclein. In pre-clinical trials it was shown to halt disease progression in animal models of MSA and PD.
